Study investigates the impact of AI on clinicians’ diagnostic accuracy, revealing that AI explanations don’t significantly mitigate the harmful effects of biased AI models, emphasizing the need for careful validation of AI tools in clinical settings.
Boehringer outlines up to $33.6m for cancer asset from OSE Therapeutics – Pharmaceutical Technology
Boehringer and OSE have been working together since 2018. Image credit: Shutterstock/ Raihana Asral. Boehringer Ingelheim has bought a preclinical oncology asset from long-time collaborator